Clinical Trial Update: A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase II study evaluating rulonilimab in combination with chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Rulonilimab (Rulonilimab)

Snippet

Sponsor: Shandong New Time Pharmaceutical Co., LTD | Conditions: Non-small Cell Lung Cancer, NSCLC | Phase 2 | Status: UNKNOWN